Rodríguez-Palma · The Journal of clinical investigation 2025 · commentary / editorial · n=>1,200,000 (referenced primary GWAS)

A high-resolution genomic roadmap for chronic pain converges on glutamatergic neurons and C-fibers.

Cited 1 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Commentary / editorial overview of primary research (CEBM Level 5)

PubMed 41392976 · doi:10.1172/JCI200554 · record verified 2026-08-28

What was done

This commentary describes a study by Toikumo et al. that integrated a chronic pain genome-wide association study (GWAS) meta-analysis (n > 1.2 million) with single-cell omics datasets from human brain regions and dorsal root ganglia to identify cell-type-specific genetic enrichments.

What was found

The abstract reports no specific numerical effect sizes, statistical thresholds, or odds ratios. It qualitatively reports that chronic pain genetic risk was enriched in central glutamatergic neurons (specifically within the prefrontal cortex, hippocampus, and amygdala) and peripheral C-fiber nociceptors (hPEP.TRPV1/A1.2 subtype), with implicated genes converging on synaptic function and neuron projection development.

Why it matters

The findings pinpoint specific central and peripheral neuronal subtypes that mediate inherited susceptibility to chronic pain, providing precise cellular targets for future translational and mechanistic research.

Limits

This publication is a brief commentary summarizing primary research rather than presenting new empirical data. The abstract provides no quantitative metrics, effect sizes, or confidence intervals. The primary study relies on bioinformatic integration of GWAS and single-cell transcriptomics, which establishes correlation and enrichment rather than direct experimental validation of causal pathways.

Cited by